Skip to main content
Premium Trial:

Request an Annual Quote

EU Authorities Clear Invitrogen, ABI Merger

NEW YORK (GenomeWeb News) – Invitrogen and Applied Biosystems today said that European Union regulatory authorities have cleared their proposed $6.7 billion merger.
 
The deal already cleared US antitrust hurdles and is expected to close on Nov. 21, the firms said.
 
ABI stockholders have until the end of the business day on Nov. 19 to elect whether they will receive all cash, all stock, or a mix of the two in consideration for their shares.
 
As reported by GenomeWeb Daily News last week, the merged company will be called Life Technologies, rather than operating under the Applied Biosystems name, as initially planned.
 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.